The Current Landscape of CDK4/6 Inhibitors in 2026: Clinical Standards and Emerging Frontiers
As of 2026, cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors represent the cornerstone of therapy for hormone receptor-positive (HR+), human epider...
Lifestyle & Learning
